| Co-Investigator(Renkei-kenkyūsha) |
KONDO Yutaka 名古屋市立大学, 大学院医学研究科, 教授 (00419897)
KAJI Noritada 名古屋大学, 大学院工学研究科, 准教授 (90402479)
OKAMOTO Yukihiro 大阪大学, 大学院基礎工学研究科, 講師 (50503918)
PARK Yeon-Su SKIグローバルテクノロジー, 責任研究員 (50543534)
ONOSHIMA Daisuke 名古屋大学, 先端ナノバイオデバイス研究センター, 特任講師 (40510219)
YUKAWA Hiroshi 名古屋大学, 先端ナノバイオデバイス研究センター, 特任講師 (30634646)
YASUI Takao 名古屋大学, 大学院工学研究科, 助教 (00630584)
RAHONG Sakon 名古屋大学, 大学院工学研究科, 研究員 (20774277)
|
|---|
| Budget Amount *help |
¥47,710,000 (Direct Cost: ¥36,700,000、Indirect Cost: ¥11,010,000)
Fiscal Year 2015: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2014: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
Fiscal Year 2013: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2012: ¥22,100,000 (Direct Cost: ¥17,000,000、Indirect Cost: ¥5,100,000)
|
|---|
| Outline of Final Research Achievements |
Not only inherent genome alternation but also acquired genome (epigenome) alternation is extremely important for people who have a high cancer or cancer death risk. In this research, we developed nanodevices to realize DNA methylation analysis, which is a typical cancer epigenome alternation, on a single DNA molecule. We demonstrated DNA methylation mapping on a single DNA molecule in the nano devices. Our developed system could analyze DNA methylation with higher accuracy and speed rather than conventional systems, and furthermore, it will help researchers to elucidate cancer pathogenic mechanism or realize early cancer diagnosis.
|
